|
Aurobindo Pharma Limited
(Reuters Code : ARBN.BO)
has effected a major break-through in the
ARV (Anti retro viral) segment by way of
inclusion of six more of its products in World
Health Organization (WHO), Geneva’s
pre-qualification list. The products included in
the list updated on 14th December,
2005 are as follows: |
|
1. |
Efavirenz tablets— 600 mg |
|
2. |
Lamivudine oral solution— 10
mg/ml |
|
3. |
Lamivudine and Zidovudine
tablets - 150/300 mg |
|
4. |
Stavudine capsules - 30
mg |
|
5. |
Stavudine capsules—40 mg |
|
6. |
Zidovudine oral solution -
50 mg/5 ml |
|
|
Following this inclusion, the total number of
Aurobindo’s ARV products on WHO’s
pre-qualification list has gone upto ten. The
products included previously are Zidovudine
tablets 300 mg, Lamivudine tablets 150 mg,
Lamivudine tablets 300 mg and Nevirapine
tablets 200 mg tablets. |
|
This is the first time that Efavirenz tablets,
an important first line agent in the treatment
of HIV/AIDS, appear on the prequalification list
of WHO. |
|
Please find below the list of Aurobindo’s
products included in the WHO pre-qualification
list for the treatment of HIV/AIDS as of 14th
December 2005: |
|
Product Name |
Strength |
Drug class
* |
|
Efavirenz tablets |
600 mg |
NNRTI |
|
Lamivudine oral solution |
10 mg/ml |
NRTI |
|
Lamivudine and Zidovudine
tablets |
150 / 300 mg |
NRTI |
|
Stavudine capsules |
30 mg |
NRTI |
|
Stavudine capsules |
40 mg |
NRTI |
|
Zidovudine oral solution |
50 mg / 5 ml |
NRTI |
|
Zidovudine tablets |
300 mg |
NRTI |
|
Lamivudine tablets |
150 mg |
NRTI |
|
Lamivudine tablets |
300 mg |
NRTI |
|
Nevirapine tablets |
200 mg |
NNRTI |
|
|
*
NRTI: Nucleoside reverse
transcriptase inhibitor
NNRTI: Non- Nucleoside reverse
transcriptase inhibitor |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The Company is
marketing these products globally, in over 100
countries. |
PRESS
ROOM
